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Abstract 
Background: Plasmodium falciparum uncomplicated malaria can successfully be treated with an artemisinin‑based 
combination therapy (ACT). However resistance is spreading to the different ACT compounds; the artemisinin deriva‑
tive and the partner drug. Studies of P. falciparum polymorphisms associated with drug resistance can provide a useful 
tool to track resistance and guide treatment policy as well as an in‑depth understanding of the development and 
spread of resistance.
Methods: The role of P. falciparum molecular markers in selection of reinfections was assessed in an efficacy trial 
comparing artesunate–amodiaquine fixed‑dose combination with artemether–lumefantrine to treat malaria in Nimba 
County, Liberia 2008–2009. P. falciparum polymorphisms in pfcrt 76, pfmdr1 86, 184 and 1246, and pfmrp1 876 and 
1466 were analysed by PCR‑RFLP and pyrosequencing.
Results: High baseline prevalence of pfmdr1 1246Y was found in Nimba county (38 %). Pfmdr1 1246Y and pfmdr1 
86+184+1246 haplotypes NYY and YYY were selected in reinfections in the artesunate–amodiaquine arm and pfcrt 
K76, pfmdr1 N86 and pfmdr1 haplotype NFD were selected in artemether–lumefantrine reinfections. Parasites har‑
bouring pfmdr1 1246Y could reinfect earlier after treatment with artesunate–amodiaquine and parasites carrying 
pfmdr1 N86 could reinfect at higher lumefantrine concentrations in patients treated with artemether–lumefantrine.
Conclusions: Although treatment is highly efficacious, selection of molecular markers in reinfections could indicate 
a decreased sensitivity or tolerance of parasites to the current treatments and the baseline prevalence of molecular 
markers should be closely monitored. Since individual drug levels and the day of reinfection were demonstrated to 
be key determinants for selection of reinfections, this data needs to be collected and taken into account for accurate 
evaluation of molecular markers for anti‑malarial treatments.
The protocols for the clinical trial was registered with Current Controlled Trials, under the Identifier Number 
ISRCTN51688713 on 9 October 2008
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Background
Plasmodium falciparum malaria is a devastating disease 
still causing high mortality and morbidity especially in 
children in sub-Saharan Africa. The uncomplicated form 
of P. falciparum infection can be easily and successfully 
treated with an artemisinin-based combination therapy 
(ACT); however there is always the threat of resistance 
development to the different ACT compounds; the arte-
misinin derivative and/or the partner drug. Studies of P. 
falciparum polymorphisms associated with drug resist-
ance can provide a useful tool to track resistance and 
guide treatment policy as well as an in-depth understand-
ing of the development and spread of resistance.
Polymorphisms in pfmdr1 and pfcrt have been shown 
to have an effect on parasite susceptibility to artesu-
nate–amodiaquine (AS–AQ) treatment, in particular 
pfcrt 76T, pfmdr1 1246Y and the pfmdr1 86-184-1246 
haplotype Y–Y–Y which has been associated with recru-
descences and reinfections [1–4]. Pfmdr1 N86, 184F and 
D1246 and pfcrt K76 alleles are repeatedly demonstrated 
to be selected in reinfections or recurrent infections after 
artemether–lumefantrine (AL) treatment [5, 6], support-
ing their role in the decreased sensitivity to lumefantrine. 
In pooled analyses, an increased risk of recrudescence 
after AL treatment was demonstrated when pfmdr1 N86 
was present [4].
Only scarce data on anti-malarial efficacy and preva-
lence of molecular resistance markers is available from 
Liberia. In 1978–1981, wildtype alleles pfcrt K76 and 
pfmdr1N86 were dominating [7]. In 2000, high clinical 
resistance to chloroquine was observed as well as high 
baseline prevalence of the chloroquine resistance marker 
pfcrt 76T (84 %) [8]. AS–AQ became the first line treat-
ment in 2003 and it was changed to AS–AQ fixed dose 
combination (ASAQ-FDC) in 2010. High efficacy of 
ASAQ-FDC and AL was demonstrated in this clinical 
trial conducted in 2008–2009 [9]. The aim of the study 
was to investigate the prevalence and selection of pfcrt 
and pfmdr1 genotypes in the clinical trial. This is the first 
study to assess molecular anti-malarial resistance mark-
ers in Liberia since the implementation of ACT. The work 
shows selection of parasite molecular markers in reinfec-
tions after treatment with both ACT and that molecular 
markers can influence the time after treatment and at 
which drug concentration a parasite is able to reinfect.
Methods
Study subjects
Analyses were performed of P. falciparum positive blood 
samples from a randomized non-inferiority efficacy trial 
evaluating ASAQ-FDC [n  =  149 (ASAQ Winthrop®, 
Sanofi-Aventis)] and AL [n = 150 (Coartem®, Novartis)], 
conducted in 2008–2009 in Saclepea Comprehensive 
Health Centre in Nimba County, Liberia-a facility at the 
time supported by Médecins Sans Frontières-Switzer-
land in collaboration with the Ministry of Health. Chil-
dren below 5 years of age were enrolled and followed for 
42 days. The protocols for the clinical trial was registered 
with Current Controlled Trials, under the identifier num-
ber ISRCTN51688713 [9]. Blood was collected from the 
patients on FTA filter papers before treatment and dur-
ing the follow up.
Parasite molecular markers in pfcrt K76T, pfmdr1 
N86Y, Y184F, D1246Y and pfmrp1 I876V and K1466R 
was assessed in pre-treatment and post-treatment sam-
ples, classified according to the 42-day PCR-adjusted 
outcome. Recrudescences and reinfections were distin-
guished by stepwise genotyping msp1, msp2 and glurp 
[9].
DNA extraction
DNA was extracted from blood spotted onto FTA filter 
papers using the QIAamp® 96 DNA Blood Kit accord-
ing to the manufacturer’s protocol for dried blood spots 
(Qiagen, Hilden, Germany).
Pyrosequencing
pfmrp1 SNPs in codons I876V and K1466R were ana-
lysed from extracted DNA by PCR amplification followed 
by pyrosequencing previously described [3]. The defini-
tion of a single genotype (pure) infection was a pyrose-
quencing result above 90 % or below 10 %, while a mixed 
genotype infection was between 10 and 90  % for both 
genotypes.
Nested‑PCR and RFLP
Pfcrt, and pfmdr1 SNPs were analysed by nested PCR fol-
lowed by restriction fragment length polymorphisms as 
previously described [3].
Determination of drug concentrations in blood and serum
Pre-treatment serum samples were tested for previous 
intake of chloroquine and quinine by liquid chromatogra-
phy coupled with tandem mass spectrometry. Pre-treat-
ment and day 7 concentrations of desethylamodiaquine 
(DAQ) and lumefantrine were analysed from venous 
blood spotted on filter paper and measured by high per-
formance liquid chromatography with ultraviolet detec-
tion (lumefantrine) or by tandem-mass spectrometry [4].
Data analyses
Fisher’s two-tailed test (GraphPad Software Inc. Sand 
Diego, CA) was used to evaluate genetic selection by 
the difference in genotype prevalence between pre-
treatment samples and recrudescences and reinfections, 
respectively. The baseline genotype prevalence was based 
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on pre-treatment samples from both treatment arms. 
Patients were excluded from the pre-treatment group 
due to incorrect enrolment and infection with other spe-
cies and from the post-treatment analysis due to infec-
tion with other species, missing or undetermined result 
from the msp1, msp2 and glurp genotyping or incom-
plete treatment. In one SNP analysis, mixed genotypes 
were analysed together with the non-selected genotypes 
against the selected genotype, as previously suggested 
[3]. For example, in the AL arm the prevalence of mixed 
alleles in position pfmdr1 86 (N+Y) was added to the 
prevalence of pfmdr1 86Y and compared to the preva-
lence of pfmdr1 N86. Mixed genotype infections were 
excluded in the haplotype analyses. Mann–Whitney U 
test was used to assess differences in drug concentrations 
at day 7 and time of reinfection in relation to parasite 
genotype. Exclusion criteria were incomplete treatment 
and missing data. Statistical significance was defined as a 
p value ≤0.05 in all analyses.
Results
Baseline prevalence of polymorphisms
Before treatment the prevalence of the pfcrt mutant allele 
76T was 93.6 %. There was large variation in the pfmdr1 
SNPs where the mutant alleles 86Y, 184F and 1246Y were 
found in 69.4, 43.6 and 38.4  % respectively (including 
mixed genotype infections). The wild type allele was pre-
dominating in pfmrp1; I876 was found in 99.3  % of the 
samples and K1466R in 97.6 % (Table 1). Previous intake 
of chloroquine, quinine or amodiaquine/DAQ (measured 
in pre-treatment serum samples), did not have significant 
impact on the baseline prevalence of pfcrt and pfmdr1 
SNPs.
Selection of polymorphisms after treatment
After treatment pfmdr1 1246Y was selected in the 
ASAQ-FDC arm, which was found in 55/294 (18.7  %) 
patients at baseline and in 24/60 (40.0  %) reinfections 
(Fisher, two-tailed, p  <  0.001) (Table  1). In the AL arm, 
a selection of pfcrt K76 and pfmdr1 N86 was identified, 
that increased in prevalence from 19/294 (6.5  %) and 
90/294 (30.6 %) at baseline to 12/38 [31.6 % (p < 0.0001)] 
and 28/40 [70.0 % (p < 0.0001)], respectively, in reinfec-
tions (Table 1). These results were confirmed when omit-
ting mixed genotype infections from the analyses. When 
studying the pfmdr1 haplotype 86+184+1246, NYY 
and YYY were selected in reinfections after ASAQ-FDC 
treatment, with a baseline prevalence of 0/198 (0 %) and 
47/198 (23.7 %) and reinfection prevalence of 2/49 [4.1 % 
(p =  0.04)] and 20/49 [40.8  % (p =  0.02)], respectively, 
while the prevalence of the wild-type haplotype NYD 
decreased from 27.8 to 10.2 % (p < 0.01). In AL reinfec-
tions the haplotype NFD was selected with a prevalence 
of 10/35 (28.6 %) compared to 29/198 (14.6 %) at baseline 
(p  =  0.05), while the prevalence of the haplotype YFD 
significantly decreased from 27.3  % at baseline to 2.9  % 
(p < 0.001).
Parasite genotypes in relation to day of reinfection 
and drug concentration
The correlation between single parasite genotypes and 
the time of reinfection or patient blood drug concentra-
tion was assessed. After ASAQ-FDC treatment, reinfect-
ing parasites harbouring pfmdr1 1246Y were observed 
earlier (median, interquartile range; 25.5, 21–35  days) 
than reinfections with parasites carrying pfmdr1 D1246 
(30, 28–37 days, p = 0.03) (Fig. 1a). There was no signifi-
cant difference in DAQ day 7 concentrations in patients 
infected with parasites with the respective genotypes. 
In patients treated with AL there was no significant dif-
ference in reinfection day between pfmdr1 N86 and 86Y 
reinfections. Lumefantrine concentrations (day 7) were 
significantly higher in patients reinfected with parasites 
carrying pfmdr1 N86 (median, interquartile range; 0.32, 
0.21–0.41 mg/L) than in patients with pfmdr1 86Y rein-
fections (0.2, 0–0.24 mg/L, p = 0.03) (Fig. 1b). All rein-
fections that occurred in patients with day 7 lumefantrine 
concentrations higher than 0.31  mg/L were caused by 
parasites carrying pfmdr1 N86. There were no significant 
differences associated with pfcrt 76 genotypes.
Discussion
Treatment with ASAQ-FDC and AL were highly effective 
against P. falciparum malaria in this clinical trial. Recru-
descences did not have a significantly lower concentra-
tion of lumefantrine or DAQ day 7 [9]. Due to the low 
number of treatment failures, statistical analyses of the 
recrudescence genotypes were not meaningful. The num-
ber of reinfections was found to be high in the AL arm 
(30.0  %) and very high in the ASAQ-FDC arm (43.0  %) 
by day 42. In the ASAQ-FDC arm selection of the mutant 
allele pfmdr1 1246Y and the haplotypes pfmdr1 YYY and 
pfmdr1 NYY in reinfections was demonstrated in Libe-
ria, showing a similar selection as observed in Tanzania 
[1] and in Mali [2]. The baseline prevalence of pfmdr1 
1246Y at the time of this trial 2008–2009 was observed 
to be higher than in other countries in West Africa [38 % 
including mixed genotype infections compared to 0–25 % 
in 19 studies (search: years 2000–2014, n < 40, from West 
Africa)] as reported in literature [10]. The high pfmdr1 
1246Y baseline prevalence may lead to the very high num-
ber of reinfections in the ASAQ-FDC arm in this trial, 
compared to the AL arm. Since 1246Y was observed to 
be selected in ASAQ-FDC reinfections, a higher base-
line prevalence of the genotype can result in a larger 
pool of pfmdr1 1246Y carrying parasites that can survive 
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the residual DAQ levels and result in more reinfections. 
Selection of pfmdr1 1246Y was observed mainly in early 
reinfections, while after day 35 the prevalence of 1246Y 
in reinfection was similar to the 1246Y prevalence before 
treatment. These results indicate that the concentration of 
DAQ was high enough to provide a selection pressure up 
to day 35. After this time-point all genotypes were able to 
survive the residual drug level and cause reinfection and 
there was no longer a protective or selective effect of the 
drug. This idea needs to be further elaborated by studying 
further efficacy trials with ASAQ and AL in West Africa. 
The 1246Y genotype has also been associated with ASAQ-
FDC treatment failures [4]. Despite the high prevalence 
of 1246Y, few treatment failures were observed in this 
study, probably due to the high efficacy of the artesunate 
compound in the combination. Artemisinin resistance is 
defined as delayed parasite clearance after treatment with 
an artemisinin or ACT [11]. In this study a low proportion 
Table 1 Number and prevalence of Plasmodium falciparum polymorphisms pre- and post-treatment and post-treatment 
selection 
Number and prevalence of polymorphisms selected post-treatment are in italics
* p ≤ 0.05, ** p < 0.001, *** p < 0.0001
a  Haplotype prevalence excluding mixed genotype infections
b  YYD, NFY, YFY
Genotype Pre‑treatment Post‑treatment
ASAQ‑FDC AL
Recrudescences Reinfections Recrudescences Reinfections
pfcrt 76
 K 19 6.5 % 0 0.0 % 2 3.3 % 1 16.7 % 12*** 31.6 %
 K/T 7 2.4 % 0 0.0 % 3 5.0 % 0 0.0 % 1 2.6 %
 T 268 91.2 % 2 100.0 % 55 91.7 % 5 83.3 % 25 65.8 %
pfmdr1 86
 N 90 30.6 % 1 50.0 % 12 19.7 % 4 66.7 % 28*** 70.0 %
 N/Y 47 16.0 % 0 0.0 % 8 13.1 % 1 16.7 % 3 7.5 %
 Y 157 53.4 % 1 50.0 % 41 67.2 % 1 16.7 % 9 22.5 %
pfmdr1 184
 Y 166 56.5 % 1 50.0 % 33 55.9 % 3 50.0 % 24 55.8 %
 Y/F 24 8.2 % 1 50.0 % 2 3.4 % 1 16.7 % 2 4.7 %
 F 104 35.4 % 0 0.0 % 24 40.7 % 2 33.3 % 17 39.5 %
pfmdr1 1246
 D 181 61.6 % 2 66.7 % 29 48.3 % 5 83.3 % 33 76.7 %
 D/Y 58 19.7 % 1 33.3 % 7 11.7 % 0 0.0 % 2 4.7 %
 Y 55 18.7 % 0 0.0 % 24** 40.0 % 1 16.7 % 8 18.6 %
pfmrp1 876
 I 285 96.9 % 2 100.0 % 59 96.7 % 6 100.0 % 42 97.7 %
 I/V 7 2.4 % 0 0.0 % 1 1.6 % 0 0.0 % 0 0.0 %
 V 2 0.7 % 0 0.0 % 1 1.6 % 0 0.0 % 1 2.3 %
pfmrp1 1466
 K 283 96.3 % 3 100.0 % 60 100.0 % 6 100.0 % 40 100.0 %
 K/R 4 1.4 % 0 0.0 % 0 0.0 % 0 0.0 % 0 0.0 %
 R 7 2.4 % 0 0.0 % 0 0.0 % 0 0.0 % 0 0.0 %
pfmdr1 86 + 184 + 1246a
 NYD 55 27.8 % 1 100.0 % 5 10.2 % 2 40.0 % 15 42.9 %
 NYY 0 0 % 0 0 % 2* 4.1 % 0 0 % 1 2.9 %
 NFD 29 14.6 % 0 0.0 % 4 8.2 % 2 40.0 % 10* 28.6 %
 YFD 54 27.3 % 0 0.0 % 15 30.6 % 0 0.0 % 1 2.9 %
 YYY 47 23.7 % 0 0.0 % 20* 40.8 % 1 20.0 % 5 14.3 %
 Othersb 13 6.6 % 0 0.0 % 3 6.1 % 0 0.0 % 3 8.6 %
Page 5 of 6Otienoburu et al. Malar J  (2016) 15:452 
of patients were parasite positive on day 3 [9], indicating 
high efficacy of the artesunate compound.
In the AL arm, the wild-type alleles pfcrt K76, pfmdr1 
N86 and the pfmdr1 haplotype NFD were selected in rein-
fecting parasites, by the drug pressure of residual levels of 
lumefantrine. Parasites harbouring pfmdr1 N86 was not 
observed to reinfect significantly earlier, as has been sug-
gested in previous studies [4, 6]. However it was demon-
strated that parasites carrying pfmdr1 N86 could cause 
reinfection in patients with higher lumefantrine concen-
trations, than parasites carrying pfmdr1 86Y. Patients 
with low lumefantrine levels could be reinfected with both 
N86 and 86Y alleles, while parasites with pfmdr1 N86 
could withstand intermediate drug concentrations. At 
high lumefantrine concentrations both genotypes would 
be killed and no reinfection could occur. This idea is sup-
ported by the observation that patients with reinfections 
had lower lumefantrine levels [9]. This is in agreement 
with an important study suggesting that reinfecting para-
sites with pfmdr1 N86 as well as the pfmdr1 N86/184F/
D1246 haplotype can withstand higher lumefantrine 
concentrations based on day 7 data [12]. Both individual 
drug levels and the day of reinfection are key determi-
nants for selection of reinfections and needs to be taken 
into account if available. This is especially important for 
AL-treated patients, in which the total lumefantrine dose 
received can vary significantly [13]. In studies from East 
Africa pfmdr1  184F is often selected in reinfections after 
AL treatment, which was not observed in this study. This 
could be due to the high baseline prevalence of pfmdr1 
NYD haplotype in this and a study in Benin [3], where 
pfmdr1 N86 could be the main driving force for lumefan-
trine resistance, independently of the pfmdr1184 genotype.
The longer elimination half-life of the partner drug is a 
double-edged sword since although it can provide some 
post-prophylactic protection of individual patients, selec-
tion of reinfections can result in a more resistant para-
site population over time. In high transmission areas, 
in Tanzania and Uganda, consistent treatment with AL 
overtime has probably resulted in significant increases 
in the prevalence of genotypes associated with AL treat-
ment failure and reinfection [14, 15]. However, tempo-
ral changes of ASAQ resistance markers have not been 
observed after consistent use of AS–AQ in Zanzibar [16].
Conclusions
In this first study investigating pfcrt and pfmdr1 poly-
morphisms after the implementation of ACT in Liberia, 
selection of molecular markers in AL and ASAQ-FDC 
reinfections and high pfmdr1 1246Y baseline prevalence 
was demonstrated. The observation that parasites carrying 
pfmdr1 N86 can reinfect patients with higher lumefantrine 
concentrations highlights the importance of studying drug 
levels after AL treatment, as there could be large inter-indi-
vidual dose variations. It is important to further investigate 
variables governing selection of reinfections in individual 
studies and as well as over time, as they can be responsible 
for the step from selection of a reinfection to full resistance 
and treatment failures. To evaluate and advise the current 
treatment policy it is essential to monitor temporal changes 
in molecular resistance markers of treatments used in Libe-
ria in conjunction with conventional efficacy testing.
Fig. 1 Plot of reinfection genotypes by day and patient blood drug concentration day 7. Each data point represents the P. falciparum genotype of a 
reinfection. a Genotype of reinfections after ASAQ‑FDC treatment and desethylamodiaquine (DAQ) concentration. Filled triangles represent reinfec‑
tions harbouring the pfmdr1 D1246 genotype and open squares represent pfmdr1 1246Y reinfections. b Genotype of reinfections after AL treatment 
and lumefantrine (LUM) concentration. Filled triangles represent reinfections harbouring the pfmdr1 N86 genotype and open squares represent 
pfmdr1 86Y reinfections
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